<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01025167</url>
  </required_header>
  <id_info>
    <org_study_id>N-SUP-09-DE</org_study_id>
    <nct_id>NCT01025167</nct_id>
  </id_info>
  <brief_title>The Effect of a New Specific Enteral Formula Compared to a Standard Formula on the Tolerability of a Combined Radio- and Chemotherapy in Cancer Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Kabi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fresenius Kabi</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the impact of a specific nutrition formula with a
      high content of eicosapentaenoic acid (EPA) and fat in oncology patients receiving
      radio-/chemotherapy on body weight, body composition, nutritional status and physical
      function compared to a standard nutrition formula. Using an adaptive design approximately 80
      patients will be randomized in the first part of the study. Following an interim analysis
      further 160 patients may be added, for a total of 240 patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body cell mass measured by bioelectrical impedance spectroscopy (BIS)</measure>
    <time_frame>Baseline, mid of radio-/chemotherapy, end of radio-/chemotherapy, day 28 of convalescence period, day 49 of convalescence period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other parameters of body composition such as fat free mass, lipid mass, total body water, intracellular water, lean tissue mass</measure>
    <time_frame>Baseline, mid of radio-/chemotherapy, end of radio-/chemotherapy, day 28 of convalescence period, day 49 of convalescence period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hand grip strength</measure>
    <time_frame>Baseline, mid of radio-/chemotherapy, end of radio-/chemotherapy, day 28 of convalescence period, day 49 of convalescence period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Baseline, end of radio-/chemotherapy, day 49 of convalescence period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal tolerance</measure>
    <time_frame>Baseline, mid of radio-/chemotherapy, end of radio-/chemotherapy, day 28 of convalescence period, day 49 of convalescence period, daily</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Enteral Nutrition</condition>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Supportan(R) (500 ml)/disease-specific enteral tube feed for oncologic patients with special key substrates</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Fresubin(R) energy fibre (500 ml)/a nutritionally complete enteral standard feed (isoenergetic)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Supportan(R) (Disease-specific enteral tube feed, food for special medical purposes)</intervention_name>
    <description>500 ml per day / treatment period 11-14 weeks</description>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fresubin(R)</intervention_name>
    <description>500 ml/a nutritionally complete enteral standard feed (isoenergetic)</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with head &amp; neck cancer or oesophagus cancer,

          -  enteral nutrition with PEG at least for 14 weeks,

          -  cancer patients who receive a combined radio-/chemotherapy,

          -  start of nutritional therapy latest at beginning of the radio-/chemotherapy, body mass
             index &gt;=16 and &lt;=30 kg/m2,0

          -  Kondrup Score&gt;=3 or SGA = B/C,

          -  life expectancy &gt; 6 months,

          -  written informed consent.

        Exclusion Criteria:

          -  second active carcinoma,

          -  severe diarrhea unresponsive to codeine/loperamide,

          -  positive anti-HIV-test (safety reasons),

          -  pregnant or lactating women,

          -  insulin-dependent diabetes mellitus type I and II,

          -  patients with cardiac pacemaker,

          -  allergy to contents of the investigational product, to milk protein or to fish oil,

          -  patient has no PEG,

          -  participation in concurrent clinical studies with any other investigational
             nutritional therapy within one months prior to start of the study,

          -  intake of muscle growth supportan substances (e.g. anabolics),

          -  additional fish oil or EPA substitution within the last 4 weeks, SGA status A (well
             nourished).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rainer Fietkau, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiotherapy University hospital of Erlangen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zentrum für Strahlentherapie und Radioonkologie, Ärztehaus am DIAKO</name>
      <address>
        <city>Bremen</city>
        <zip>D-28239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>D-01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Radiotherapy, University hospital</name>
      <address>
        <city>Erlangen</city>
        <zip>D-91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>D-60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abteilung Strahlentherapie und Radioonkologie, Universitätsmedizin Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>D-37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Strahlentherapie, Universitätsklinikum Halle</name>
      <address>
        <city>Halle</city>
        <zip>D-06097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg (Saar)</city>
        <zip>D-66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Strahlentherapie Universität Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>D-18059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abteilung Strahlentherapie und Radioonkologie, Universitätsmedizin Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>D-89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2009</study_first_submitted>
  <study_first_submitted_qc>December 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2009</study_first_posted>
  <last_update_submitted>August 19, 2010</last_update_submitted>
  <last_update_submitted_qc>August 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Steffen Benzing</name_title>
    <organization>Kabi Innovation Centre, Fresenius Kabi Deutschland GmbH</organization>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>enteral nutrition</keyword>
  <keyword>omega-3-fatty acids</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

